EGFR and neoplasm: Similarly, considering the PPV (91.2%, 31/34) and NPV (67.1%, 49/73) of EGFR detection with CastPCR in our study, for patients whose tumor tissue is not enough or unavailable, EGFR mutation detection with CastPCR in cfDNA could be first choice.